XML 43 R32.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

REVENUE (Tables) | 6 Months Ended
--- | ---
Apr. 30, 2024
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended April 30,
| 2024 |  | 2023
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 240 |  |  | $ | 167 |  |  | $ | 230 |  |  | $ | 637 |  |  | $ | 263 |  |  | $ | 154 |  |  | $ | 259 |  |  | $ | 676 |
Europe | 188 |  |  | 111 |  |  | 127 |  |  | 426 |  |  | 207 |  |  | 103 |  |  | 123 |  |  | 433 |
Asia Pacific | 326 |  |  | 124 |  |  | 60 |  |  | 510 |  |  | 404 |  |  | 130 |  |  | 74 |  |  | 608 |
Total | $ | 754 |  |  | $ | 402 |  |  | $ | 417 |  |  | $ | 1,573 |  |  | $ | 874 |  |  | $ | 387 |  |  | $ | 456 |  |  | $ | 1,717 |
| Six Months Ended April 30,
| 2024 |  | 2023
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 484 |  |  | $ | 331 |  |  | $ | 452 |  |  | $ | 1,267 |  |  | $ | 549 |  |  | $ | 308 |  |  | $ | 506 |  |  | $ | 1,363 |
Europe | 412 |  |  | 222 |  |  | 250 |  |  | 884 |  |  | 446 |  |  | 201 |  |  | 242 |  |  | 889 |
Asia Pacific | 704 |  |  | 254 |  |  | 122 |  |  | 1,080 |  |  | 822 |  |  | 259 |  |  | 140 |  |  | 1,221 |
Total | $ | 1,600 |  |  | $ | 807 |  |  | $ | 824 |  |  | $ | 3,231 |  |  | $ | 1,817 |  |  | $ | 768 |  |  | $ | 888 |  |  | $ | 3,473 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended |  | Six Months Ended
| April 30, |  | April 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
| (in millions)
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical and Biopharmaceutical | $ | 542 |  |  | $ | 612 |  |  | $ | 1,107 |  |  | $ | 1,251 |
Chemicals and Advanced Materials | 362 |  |  | 378 |  |  | 754 |  |  | 784 |
Diagnostics and Clinical | 239 |  |  | 250 |  |  | 467 |  |  | 489 |
Food | 139 |  |  | 161 |  |  | 296 |  |  | 321 |
Academia and Government | 139 |  |  | 159 |  |  | 289 |  |  | 305 |
Environmental and Forensics | 152 |  |  | 157 |  |  | 318 |  |  | 323 |
Total | $ | 1,573 |  |  | $ | 1,717 |  |  | $ | 3,231 |  |  | $ | 3,473 |
Revenue by Type |  |  |  |  |  |  |
Instrumentation | $ | 548 |  |  | $ | 689 |  |  | $ | 1,178 |  |  | $ | 1,448 |
Non-instrumentation and other | 1,025 |  |  | 1,028 |  |  | 2,053 |  |  | 2,025 |
Total | $ | 1,573 |  |  | $ | 1,717 |  |  | $ | 3,231 |  |  | $ | 3,473 |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the six months ended April 30, 2024:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2023 |  | $ | 616 |
Net revenue deferred in the period |  | 393 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (350) |
Change in deferrals from customer cash advances, net of revenue recognized |  | (6) |
Currency translation and other adjustments |  | 1 |
Ending balance as of April 30, 2024 |  | $ | 654 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration